Form 4: Nuvalent CEO Sells Shares Under 10b5-1 Plan

Nuvalent Inc.'s President and CEO, James Richard Porter, sold 27,000 shares of Class A Common Stock on August 15, 2025, following the exercise of stock options, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• James Richard Porter, President and CEO of Nuvalent, Inc., engaged in transactions involving the company's Class A Common Stock on August 15, 2025.
• Porter exercised stock options to acquire 27,000 shares at an exercise price of $18.93 per share.
• Concurrently, Porter sold a total of 27,000 shares of Class A Common Stock in multiple transactions.
• The sales occurred at weighted average prices of $75.22 (20,035 shares), $75.98 (6,865 shares), and $76.90 (100 shares).
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on April 2, 2024.
• Following these transactions, Porter directly beneficially owns 249,062 shares of Class A Common Stock and 276,400 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, the fact that it was conducted under a Rule 10b5-1 plan mitigates concerns about its implications for the company's future prospects. The significant profit realized from the option exercise is a positive for the executive.

Positives

• The exercise of stock options at a price of $18.93 and subsequent sale at significantly higher prices (ranging from $74.67 to $76.90) indicates a substantial profit for the insider on these specific transactions.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sales were not based on new, undisclosed material information.

Negatives

• The sale of 27,000 shares by a key executive, even if pre-planned, represents a reduction in direct insider ownership of common stock.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some as a lack of confidence, though the pre-planned nature typically mitigates this. The overall impact is likely minimal given the context.

Key Dates

Recommendation

The filing details routine insider transactions under a Rule 10b5-1 plan, which are pre-scheduled and do not typically signal new information about the company's performance or outlook. While the executive sold shares, this was immediately preceded by an option exercise, indicating a liquidity event rather than a change in fundamental view. There is no new information in this filing to warrant a change in investment thesis; therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals and market conditions.

Keywords

Nuvalent, NUVL, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Executive Compensation, Biotechnology, Pharmaceuticals